CJC-1295 (without DAC) vs Propranolol
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both CJC-1295 (without DAC) and Propranolol affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 (without DAC) Propranolol
Weight 3,367.97 Da 259.34 Da
Half-life 30 minutes - 2 hours ~4-5 hours
Chain 30 amino acids —
Type GHRH analog Aryloxypropanolamine derivative (C16H21NO2)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Propranolol
01 Rapid reduction of elevated heart rate within 30-60 minutes of oral dosing
02 Effective against tachycardia from both trenbolone and clenbuterol through non-selective beta blockade
03 Well-established anxiolytic effect for performance anxiety without cognitive impairment or sedation
04 Short half-life allows flexible as-needed dosing without prolonged hemodynamic effects
05 Extensive clinical safety data spanning over 50 years of use
06 Inexpensive and widely available as a generic medication
07 Does not cause dependence or withdrawal symptoms typical of benzodiazepines
08 Effective for controlling physical anxiety symptoms (tremor, palpitations, sweating)
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Propranolol
10-80 mg/day / 1-3 times daily (or as needed)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Propranolol
Fatigue and reduced exercise tolerance, particularly during the first week of use
Cold extremities (hands and feet) due to beta-2 blockade of peripheral vasodilation
Bradycardia (heart rate below 60 bpm), usually dose-dependent and asymptomatic
Dizziness or lightheadedness, especially when standing quickly
Gastrointestinal discomfort (nausea, diarrhea, constipation)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Asthma or severe reactive airway disease (non-selective beta blockade can trigger life-threatening bronchospasm)
Decompensated heart failure or cardiogenic shock
Sinus bradycardia (resting HR below 50 bpm) or second/third-degree heart block
Severe peripheral arterial disease or Raynaud's syndrome
Pheochromocytoma without prior alpha blockade (risk of hypertensive crisis from unopposed alpha stimulation)
Research Evidence
CJC-1295 (without DAC) Propranolol
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.